ReportQuality of life impairment in hidradenitis suppurativa: A study of 61 cases
Section snippets
Physician-assessed clinical grading
In all, 61 consecutive patients referred to our specialized HS consultation service were prospectively evaluated by one of us (J. R.) during a period of 6 months. For each patient a case report form was completed including demographic characteristics, details of the course of the disease (eg, age at onset, continuous or intermittent disease), and details of the lesions. The outcome variables suggested by Sartorius et al5 were used to quantify disease intensity. The score of Sartorius et al5 was
Study population
In all, 61 patients (47 women and 14 men) were included in our study. Their mean age was 37.8 ± 11.5 years. The score of Sartorius et al5 was 25.1 ± 18.2 (range: 2-97). The self-reported disease duration was between 1 and 5 years for 11 patients, between 6 and 10 years for 21, between 11 and 19 years for 14, and more than 20 years for 13 (missing data: n = 2). A total of 28 patients had an intermittent disease and 27 had a continuous evolution (missing data: n = 6). The score of the visual
Discussion
Our findings are in agreement with previously published data confirming that HS has a significant impact on QoL.2, 3 The scores found for HS in our study showed much more impairment than those found in several other dermatologic conditions, including chronic urticaria, psoriasis, atopic dermatitis, and neurofibromatosis 1, all conditions traditionally regarded as causing significant disability.7, 8 Compared with these diseases, one can conclude that HS is a distressing condition for many
References (10)
- et al.
The French SF-36 health survey: translation, cultural adaptation and preliminary psychometric evaluation
J Clin Epidemiol
(1998) Effect of localized surgical excisions in hidradenitis suppurativa
J Am Acad Dermatol
(1988)- et al.
The natural history of hidradenitis suppurativa
J Eur Acad Dermatol Venereol
(2000) - et al.
Morbidity in patients with hidradenitis suppurativa
Br J Dermatol
(2001) - et al.
Hidradenitis suppurativa–characteristics and consequences
Clin Exp Dermatol
(1996)
Cited by (330)
Diagnosis and management of perineal hidradenitis suppurativa: What the urologist needs to know
2024, Progres en Urologie - FMCCervicofacial hidradenitis suppurativa: A case report and literature review
2023, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyRifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients
2023, Journal of the American Academy of DermatologyS2k guideline for the treatment of hidradenitis suppurativa/acne inversa (ICD-10 code L73.2)
2024, Aktuelle DermatologieFactors Affecting Treatment Selection among Patients with Hidradenitis Suppurativa
2024, JAMA DermatologyReducing the pain of hidradenitis suppurativa wounds
2024, Journal of Wound Care
Supported by PHRC 2005 (Hospital Clinical Research Program).
Conflicts of interest: None identified.